NasdaqGM:IOVABiotechs
Assessing Iovance Biotherapeutics (IOVA) Valuation After New Real World Amtagvi Data In Advanced Melanoma
Iovance Biotherapeutics (IOVA) recently reported real world data suggesting its commercial TIL therapy Amtagvi may have a best in class profile with strong response rates in advanced melanoma, which has refocused attention on the stock.
See our latest analysis for Iovance Biotherapeutics.
The real world Amtagvi data arrives after a volatile few years for shareholders. The recent 30 day share price return of 15.77% and a 1 day move of 1.98% at a US$2.57 share price stand in contrast to a 1...